Long-term fostamatinib use for warm autoimmune anemia
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study checks the benefits and safety of continuing fostamatinib over the long term for people with warm autoimmune hemolytic anemia. It may help by reducing the body’s immune attack on red blood cells, and it’s designed for people who already finished a prior part of the study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be able and willing to sign the study consent form before any study steps begin.
- You must have finished the previous study’s full 24 weeks.
- You must not have stopped the earlier study before Week 24.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks the long-term safety of felzartamab for people who have had a kidney transplant and are dealing with antibody-mediated rejection or signs of inflammation in the kidney. It's for those who were already in a previous study and took at least one dose of felzartamab.
This trial tests a new cell therapy, FT819, for people with certain autoimmune diseases like lupus, vasculitis, myositis, or scleroderma that haven't improved with at least two previous treatments. The goal is to see if it can help control the disease.
This study follows people with chronic immune thrombocytopenia (ITP) who are starting fostamatinib for the first time. It aims to gather information on how well the medicine works and how safe it is when used over a longer period.
This trial tests a drug called fostamatinib to see if it can help people with a severe lung condition called ARDS, which causes breathing failure. If you are in the hospital on a breathing machine, this drug might help your lungs recover.
This trial tests a new medicine called fostamatinib for people who have had a lung transplant and have developed donor-specific antibodies (DSA) on their lung. The goal is to see if this medicine is safe and can help prevent the body from rejecting the new lung.
This study tests a medication called fostamatinib to see if it is safe and tolerable for people with sickle cell disease. It may offer a new treatment option for managing the condition.
Hear when a new Warm Antibody Autoimmune Hemolytic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.